retatrutide fda approval status eli lilly Lilly's experimental obesity drug is not available to the public., But exclusive reporting from our editorial partners at @statnews found that this spring the allowed one person -- LLY $NVO Eli Lilly announced

Traditionally GLP-1(9-36) was considered inactive, however more recent studies indicate that GLP-1(9-36) can contribute to inhibiting glucagon secretion by inhibiting voltage-gated calcium channels through a GPCR mechanism, an effect which reduces the number of glucagon containing vesicles that are available for exocytosis, thereby contributing the the decrease in glucagon secretion (Figure 1)(Zheng et al, 2024)

This is why SCFAs and metabolic health are closely connected, since these microbial metabolites help link gut bacteria, inflammation control, glucose regulation, and appetite signaling

J Med Chem 58(18):73707380

In contrast, high glucose contents attenuate intestinal AMPK activation

If that makes you have some feelings, 23-time Grand Slam champion and decorated Olympian Serena Williams understands

This is a question I wish more people would ask